arm_1
1 clinical trial
1 product
1 indication
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
STRO-002 + bevacizumabIndication
recurrent epithelial ovarian cancer